Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Corneal lymphangiogenesis as a potential target in dry eye disease - a systematic review.

Tytuł:
Corneal lymphangiogenesis as a potential target in dry eye disease - a systematic review.
Autorzy:
Chennakesavalu M; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Somala SRR; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Dommaraju SR; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Peesapati MP; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Guo K; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Rosenblatt MI; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Chang JH; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL. Electronic address: .
Azar DT; Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, College of Medicine, University of Illinois at Chicago, Chicago, IL.
Źródło:
Survey of ophthalmology [Surv Ophthalmol] 2021 Nov-Dec; Vol. 66 (6), pp. 960-976. Date of Electronic Publication: 2021 Mar 31.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; Systematic Review
Język:
English
Imprint Name(s):
Original Publication: New York, NY : Elsevier Science,
MeSH Terms:
Dry Eye Syndromes*/etiology
Lacrimal Apparatus*
Lymphatic Vessels*
Cornea ; Humans ; Lymphangiogenesis/physiology
References:
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):421-9. (PMID: 25524775)
J Ocul Pharmacol Ther. 2020 Apr;36(3):137-146. (PMID: 32175799)
Ophthalmology. 2017 Nov;124(11S):S4-S13. (PMID: 29055361)
Int J Mol Sci. 2017 May 05;18(5):. (PMID: 28475124)
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):79-86. (PMID: 28061513)
Vet Pathol. 2013 Jan;50(1):7-22. (PMID: 23345459)
J Cell Mol Med. 2019 Nov;23(11):7602-7616. (PMID: 31456353)
Invest Ophthalmol Vis Sci. 2013 May 03;54(5):3082-93. (PMID: 23580490)
Expert Opin Drug Saf. 2008 Jan;7(1):79-89. (PMID: 18171316)
J Ophthalmol. 2016;2016:7542929. (PMID: 27042343)
J Immunol. 2006 Apr 1;176(7):3950-7. (PMID: 16547229)
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2545-52. (PMID: 17525183)
Med Res Rev. 2018 Sep;38(6):1769-1798. (PMID: 29528507)
Dtsch Arztebl Int. 2015 Jan 30;112(5):71-81; quiz 82. (PMID: 25686388)
J Exp Med. 2011 May 9;208(5):1083-92. (PMID: 21536744)
Drug Saf. 2004;27(9):649-60. (PMID: 15230646)
Invest Ophthalmol Vis Sci. 2014 Apr 29;55(5):3320-7. (PMID: 24781940)
Ocul Surf. 2014 Oct;12(4):252-66. (PMID: 25284771)
Ocul Surf. 2016 Apr;14(2):207-15. (PMID: 26807723)
Invest Ophthalmol Vis Sci. 2007 Jun;48(6):2553-60. (PMID: 17525184)
Drug Saf. 2002;25(4):233-50. (PMID: 11994027)
EMBO J. 2005 Aug 17;24(16):2885-95. (PMID: 16052207)
Saudi J Ophthalmol. 2014 Jul;28(3):173-81. (PMID: 25278793)
Nat Med. 2009 Sep;15(9):1023-30. (PMID: 19668192)
Adv Ther. 2020 Jan;37(1):329-341. (PMID: 31741283)
Pharm Res. 2019 Jan 7;36(2):36. (PMID: 30617777)
Am J Ophthalmol. 2019 Jun;202:47-54. (PMID: 30721689)
Medicine (Baltimore). 2019 Aug;98(31):e16710. (PMID: 31374063)
J Clin Invest. 2005 Sep;115(9):2363-72. (PMID: 16138190)
Invest Ophthalmol Vis Sci. 2006 Jul;47(7):2847-56. (PMID: 16799024)
Int J Ophthalmol. 2016 Feb 18;9(2):218-24. (PMID: 26949638)
Ocul Immunol Inflamm. 2021 Feb 17;29(2):266-277. (PMID: 31702421)
Dev Biol. 1997 Aug 1;188(1):96-109. (PMID: 9245515)
EMBO J. 2002 Apr 2;21(7):1505-13. (PMID: 11927535)
Clin Ophthalmol. 2018 Feb 05;12:289-299. (PMID: 29440872)
J Clin Cell Immunol. 2014;5:. (PMID: 25580370)
PLoS One. 2020 Jun 5;15(6):e0234186. (PMID: 32502179)
Drugs. 2017 Feb;77(2):201-208. (PMID: 28058622)
Prog Retin Eye Res. 2010 May;29(3):208-48. (PMID: 20100589)
J Cell Mol Med. 2014 Aug;18(8):1491-508. (PMID: 24237862)
Invest Ophthalmol Vis Sci. 2012 Mar 09;53(3):1244-50. (PMID: 22281820)
JCI Insight. 2018 Feb 8;3(3):. (PMID: 29415888)
Exp Eye Res. 2013 Dec;117:1-3. (PMID: 24280033)
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1050-1062. (PMID: 30897620)
Cells. 2019 Mar 21;8(3):. (PMID: 30901976)
Ocul Surf. 2007 Apr;5(2):75-92. (PMID: 17508116)
Mil Med Res. 2015 Dec 21;2:35. (PMID: 26697189)
Sci Rep. 2019 Aug 23;9(1):12331. (PMID: 31444394)
Proc Natl Acad Sci U S A. 2006 Jul 25;103(30):11405-10. (PMID: 16849433)
Blood. 2011 Oct 27;118(17):4630-4. (PMID: 21908425)
Ocul Surf. 2015 Jul;13(3):213-25. (PMID: 26045239)
Chin Med J (Engl). 2014;127(13):2407-12. (PMID: 24985574)
Ocul Surf. 2014 Apr;12(2):87-99. (PMID: 24725321)
Clin Ophthalmol. 2015 May 20;9:877-84. (PMID: 26056426)
Cell. 2010 Feb 19;140(4):460-76. (PMID: 20178740)
Arch Ophthalmol. 2012 Jan;130(1):90-100. (PMID: 22232476)
Invest Ophthalmol Vis Sci. 2014 Jul 01;55(8):4813-22. (PMID: 24985477)
Biotech Histochem. 2008 Jun;83(3-4):179-89. (PMID: 18846440)
J Clin Invest. 2004 Apr;113(7):1040-50. (PMID: 15057311)
Surv Ophthalmol. 2020 Jan - Feb;65(1):1-11. (PMID: 31306671)
Am J Pathol. 2011 Apr;178(4):1922-9. (PMID: 21435468)
Arch Ophthalmol. 2012 Jan;130(1):84-9. (PMID: 21911653)
Dev Dyn. 2002 Nov;225(3):351-7. (PMID: 12412020)
Invest Ophthalmol Vis Sci. 2014 Oct 14;55(10):6440-2. (PMID: 25315233)
J Ophthalmic Vis Res. 2011 Jul;6(3):192-8. (PMID: 22454735)
J Clin Med. 2019 Sep 11;8(9):. (PMID: 31514344)
Invest Ophthalmol Vis Sci. 2004 Jun;45(6):1758-62. (PMID: 15161837)
Br J Pharmacol. 2006 Jun;148(3):245-54. (PMID: 16604091)
Jpn J Ophthalmol. 2010 May;54(3):199-205. (PMID: 20577852)
Am J Ophthalmol. 2012 Jul;154(1):63-71. (PMID: 22541929)
Blood Cells Mol Dis. 2007 May-Jun;38(3):258-68. (PMID: 17344076)
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15894-9. (PMID: 22967508)
Asia Pac J Ophthalmol (Phila). 2015 Jan-Feb;4(1):9-13. (PMID: 26068607)
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3802-7. (PMID: 19339740)
Drug Des Devel Ther. 2015 Jun 12;9:3043-50. (PMID: 26109847)
Cornea. 2011 Dec;30(12):1465-72. (PMID: 21993466)
Clin Ophthalmol. 2009;3:405-12. (PMID: 19688028)
J Clin Med. 2020 Feb 09;9(2):. (PMID: 32050484)
Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11658-63. (PMID: 15289610)
PLoS One. 2016 Feb 01;11(2):e0147846. (PMID: 26828208)
Ocul Surf. 2017 Oct;15(4):802-812. (PMID: 28797892)
Arch Ophthalmol. 2010 Jul;128(7):819-24. (PMID: 20625040)
Mucosal Immunol. 2009 May;2(3):243-53. (PMID: 19242409)
FEBS Lett. 2008 Jul 23;582(17):2515-20. (PMID: 18570894)
Cornea. 2014 Jun;33(6):621-7. (PMID: 24727637)
Mol Biol Cell. 2006 Feb;17(2):576-84. (PMID: 16291864)
Cell Death Dis. 2014 Jun 26;5:e1309. (PMID: 24967971)
Nature. 2006 Oct 26;443(7114):993-7. (PMID: 17051153)
Cornea. 2016 Jun;35(6):741-8. (PMID: 27055211)
PLoS One. 2015 Mar 20;10(3):e0120284. (PMID: 25793763)
Trans Am Ophthalmol Soc. 2006;104:264-302. (PMID: 17471348)
Front Bioeng Biotechnol. 2018 Feb 12;6:7. (PMID: 29484295)
Mol Cell Biol. 2007 Jan;27(2):595-604. (PMID: 17101772)
Ocul Surf. 2005 Oct;3(4 Suppl):S177-9. (PMID: 17216114)
Ocul Immunol Inflamm. 2019;27(2):266-275. (PMID: 28910552)
Proc Natl Acad Sci U S A. 1998 Jan 20;95(2):548-53. (PMID: 9435229)
J Exp Med. 2010 Jan 18;207(1):101-15. (PMID: 20026662)
J Immunol. 2009 Feb 1;182(3):1247-52. (PMID: 19155469)
Ocul Surf. 2018 Jul;16(3):306-313. (PMID: 29601983)
Community Eye Health. 2017;30(99):S1-S2. (PMID: 29849435)
J Biol Chem. 2010 Apr 9;285(15):11714-29. (PMID: 20145243)
Eye Contact Lens. 2014 Jul;40(4):248-56. (PMID: 25390549)
Ocul Immunol Inflamm. 2010 Oct;18(5):352-61. (PMID: 20735287)
Indian J Ophthalmol. 2018 Feb;66(2):190-194. (PMID: 29380756)
Exp Eye Res. 2006 Sep;83(3):526-35. (PMID: 16643899)
Biomolecules. 2018 Jan 04;8(1):. (PMID: 29300337)
Cancer Res. 2013 Jul 15;73(14):4212-21. (PMID: 23695550)
J Ophthalmol. 2019 Aug 20;2019:9613923. (PMID: 31531237)
Ocul Surf. 2018 Oct;16(4):470-477. (PMID: 30055331)
Int J Mol Sci. 2017 Jun 29;18(7):. (PMID: 28661456)
JAMA Ophthalmol. 2015 Oct;133(10):1117-23. (PMID: 26204109)
Exp Eye Res. 2020 Aug;197:108090. (PMID: 32522478)
Int J Ophthalmol. 2016 Nov 18;9(11):1541-1548. (PMID: 27990354)
Arch Med Sci. 2015 Mar 16;11(1):57-66. (PMID: 25861290)
Grant Information:
I01 BX004234 United States BX BLRD VA; R01 EY027912 United States EY NEI NIH HHS
Contributed Indexing:
Keywords: angiogenesis; anti-lymphangiogenic strategies; corneal lymphangiogenesis; dry eye; dry eye disease
Entry Date(s):
Date Created: 20210403 Date Completed: 20220330 Latest Revision: 20230308
Update Code:
20240105
PubMed Central ID:
PMC9991079
DOI:
10.1016/j.survophthal.2021.03.007
PMID:
33811911
Czasopismo naukowe
Dry eye disease (DED) is a common ocular surface condition causing symptoms of significant discomfort, visual disturbance, and pain. With recent advancements, DED has become recognized as a chronic self-perpetuating inflammatory condition triggered by various internal and environmental factors. DED has been shown to arise from the activation of both the innate and adaptive immune systems, leading to corneal epithelium and lacrimal gland dysfunction. While the cornea is normally avascular and thus imbued with angiogenic and lymphangiogenic privilege, various DED models have revealed activated corneal antigen-presenting cells in regional lymph nodes, suggesting the formation of new corneal lymphatic vessels in DED. The recent availability of reliable lymphatic cell surface markers such as LYVE-1 has made it possible to study lymphangiogenesis. Accordingly, numerous studies have been published within the last decade discussing the role of lymphangiogenesis in DED pathology. We systematically review the literature to identify and evaluate studies presenting data on corneal lymphangiogenesis in DED. There is considerable evidence supporting corneal lymphangiogenesis as a central mediator of DED pathogenesis. These findings suggest that anti-lymphangiogenic therapeutic strategies may be a viable option for the treatment of DED, a conclusion supported by the limited number of reported clinical trials examining anti-lymphangiogenic modalities in DED.
Competing Interests: Declaration of competing interests The authors report no commercial or proprietary interest in any product or concept discussed in this article.
(Copyright © 2021. Published by Elsevier Inc.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies